BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36285391)

  • 1. [Efficacy and Safety of Radiotherapy Combined with Immunotherapy
for Brain Metastases from Lung Cancer: A Meta-analysis].
    Xu L; Chen Y; Wang M
    Zhongguo Fei Ai Za Zhi; 2022 Oct; 25(10):715-722. PubMed ID: 36285391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang Y; Deng L; Yang Y; Zhang T; Wu Y; Wang L; Bi N
    Clin Lung Cancer; 2022 Mar; 23(2):95-107. PubMed ID: 34284948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
    Colaco RJ; Martin P; Kluger HM; Yu JB; Chiang VL
    J Neurosurg; 2016 Jul; 125(1):17-23. PubMed ID: 26544782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy versus surgery for early-stage non-small cell lung cancer: an updated meta-analysis involving 29,511 patients included in comparative studies.
    Viani GA; Gouveia AG; Yan M; Matsuura FK; Moraes FY
    J Bras Pneumol; 2022; 48(3):e20210390. PubMed ID: 35508065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.
    Nardone V; Nanni S; Pastina P; Vinciguerra C; Cerase A; Correale P; Guida C; Giordano A; Tini P; Reginelli A; Cappabianca S; Pirtoli L
    Strahlenther Onkol; 2019 Aug; 195(8):734-744. PubMed ID: 31123785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of EGFR Tyrosine Kinase Inhibitors Combined with Cranial Radiotherapy for Brain Metastases from Non-Small-Cell Lung Cancer: A Protocol for a Systematic Review and Meta-Analysis.
    Ge Y; Xu B; Wang H; Gao J; Zhang X; Lu T; Gao R; Li J
    Biomed Res Int; 2022; 2022():6531748. PubMed ID: 35872868
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis.
    Wang C; Lu X; Lyu Z; Bi N; Wang L
    Lung Cancer; 2018 Aug; 122():94-99. PubMed ID: 30032853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis.
    He Q; Zhang C; Tang S; Li J; Ren Q
    Transl Cancer Res; 2020 Oct; 9(10):5909-5924. PubMed ID: 35117204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for brain metastases in patients with non-small cell lung cancer: a meta-analysis of 43 studies.
    Chen S; Hua X; Jia J; Wu Y; Wei S; Xu L; Han S; Zhang H; Zhu X
    Ann Palliat Med; 2021 Apr; 10(4):3657-3672. PubMed ID: 33832315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
    Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
    Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis.
    Najafi M; Jahanbakhshi A; Gomar M; Iotti C; Giaccherini L; Rezaie O; Cavallieri F; Deantonio L; Bardoscia L; Botti A; Sardaro A; Cozzi S; Ciammella P
    Curr Oncol; 2022 Apr; 29(5):2995-3012. PubMed ID: 35621634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer.
    Zhang B
    Medicine (Baltimore); 2023 Sep; 102(36):e34572. PubMed ID: 37682155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of apatinib+radiotherapy
    Pan H; Zhou X; Shen L; Li Y; Dong W; Wang S; Zhang Y; Pan W; Xie C; Cai X
    Br J Radiol; 2023 Sep; 96(1149):20220550. PubMed ID: 37162165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of gross tumor volume in the prognosis of non-small cell lung cancer treated with 3D conformal radiotherapy: a meta-analysis.
    Yu Y; Guan H; Xing LG; Xiang YB
    Clin Ther; 2015 Oct; 37(10):2256-66. PubMed ID: 26293808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.